Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/25/2021 | $5.00 → $9.00 | Buy | HC Wainwright & Co. |
Aethlon Medical (NASDAQ:AEMD) reported quarterly losses of $(0.91) per share which beat the analyst consensus estimate of $(1.25) by 27.2 percent.
Aethlon Medical (NASDAQ:AEMD) reported quarterly losses of $(4.86) per share which beat the analyst consensus estimate of $(5.22) by 6.9 percent.
HC Wainwright & Co. analyst Vernon Bernardino maintains Aethlon Medical (NASDAQ:AEMD) with a Buy and lowers the price target from $10 to $7.
S-8 - AETHLON MEDICAL INC (0000882291) (Filer)
10-Q - AETHLON MEDICAL INC (0000882291) (Filer)
8-K - AETHLON MEDICAL INC (0000882291) (Filer)
HC Wainwright & Co. reiterated coverage of Aethlon Medical with a rating of Buy and set a new price target of $9.00 from $5.00 previously
HC Wainwright & Co. initiated coverage of Aethlon Medical with a rating of Buy and set a new price target of $5.00
SC 13G/A - AETHLON MEDICAL INC (0000882291) (Subject)
SC 13G - AETHLON MEDICAL INC (0000882291) (Subject)
SC 13G/A - AETHLON MEDICAL INC (0000882291) (Subject)
Achieves Key Milestone with Enrollment of First Two Patients in the Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies Two Australian Sites Open For Patient Enrollment in Hemopurifier® Cancer Trial Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, Nov. 13, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2024 and provided an update on recent developments. Company Updates During the seco
Received Two Australian Ethics Committee Approvals for a Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies; Expects to Open Patient Enrollment in October of 2024 Achieved Significant 24% Reduction in Fiscal First Quarter Operating Expenses Compared to the Same Period in 2023 Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, Aug. 14, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal first quarter ended June 30, 2024 and p
SAN DIEGO, Aug. 6, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal first quarter ended June 30, 2024, at 4:15 p.m. ET on Wednesday, August 14, 2024. Management will host a conference call on Wednesday, August 14, 2024, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference by navigating to https://dpregister.com/sreg/10191735/fd44630e3d. Ple
4 - AETHLON MEDICAL INC (0000882291) (Issuer)
4 - AETHLON MEDICAL INC (0000882291) (Issuer)
4 - AETHLON MEDICAL INC (0000882291) (Issuer)
Achieves Key Milestone with Enrollment of First Two Patients in the Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies Two Australian Sites Open For Patient Enrollment in Hemopurifier® Cancer Trial Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, Nov. 13, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2024 and provided an update on recent developments. Company Updates During the seco
Patient Enrolled at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO, Nov. 11, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced enrollment of the first patient in its Australian safety, feasibility and dose-finding clinical trial of the Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda
MIAMI, Oct. 30, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 76th Emerging Growth Conference on October 30 & 31, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Sponsor:QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions(844) [email protected]